Minerva Neurosciences (NERV) investor relations material

Executive summary

• Roluperidone is in a confirmatory Phase 3 trial for negative symptoms in schizophrenia, with topline efficacy results expected in H2 2027 and relapse data in H2 2028.

• No regulatory approvals or product revenue to date; significant operating losses are ongoing and expected to persist.

• Seltorexant royalty rights were sold to Royalty Pharma for $60M upfront and up to $95M in milestones, contingent on Janssen's progress.

• Scientific Advisory Board expanded to 11 members to guide the Phase 3 trial and future pipeline programs.

• Thought leadership advanced through publication analyzing negative symptoms in schizophrenia.

Financial highlights

• Q2 2026 GAAP net income was $17.5M, compared to a net loss of $3.3M in Q2 2025, driven by a $27.6M non-cash gain from warrant liability revaluation.

• For the six months ended June 30, 2026, GAAP net loss was $107.9M, primarily due to an $81.8M non-cash loss from warrant liability changes and a $6.6M one-time non-cash stock option modification charge.

• Research and development expenses rose to $7.2M in Q2 2026 (from $1.3M) and $12.4M for the six months (from $2.7M), mainly due to C19 trial costs and higher compensation.

• General and administrative expenses increased to $3.5M in Q2 2026 (from $2.1M), reflecting higher professional fees and a one-time $6.6M non-cash stock option modification charge.

• Cash, cash equivalents, marketable securities, and restricted cash totaled $75.4M as of June 30, 2026.

Outlook and guidance

• Current liquidity is expected to cover operating commitments for at least 12 months from the reporting date.

• Ongoing C19 Phase 3 trial for roluperidone is the primary focus, with topline results anticipated in H2 2027 and relapse data in H2 2028.

• Additional capital will be required to advance development and commercialization beyond current cash runway.

• Focus remains on execution of the confirmatory Phase 3 trial and advancing roluperidone as a first-in-class treatment.